09/781,023

WEST

Freeform Search

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: tumor peptide pulsed DC

Display: 15 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences | Cases

Search History

DATE: Thursday, October 24, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L10	tumor peptide pulsed DC	1	L10
L9	exosomes	14	L9
L8	L7 and cancer treatment	0	L8
L7	urine retentate	8	L7
L6	urine and cancer treatment	542	L6
L5	L4 and cancer	3	L5
L4	urine isolate	7	L4
L3	6436411.pn.	1	L3
L2	us006436411	0	L2
L1	usoo6436411	0	L1

END OF SEARCH HISTORY

WEST

Generate Collection Print

L9: Entry 1 of 14 File: USPT Oct 22, 2002

DOCUMENT-IDENTIFIER: US 6468758 B1
TITLE: Compositions and methods for ovarian cancer therapy and diagnosis

Detailed Description Text (74):
Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinmân, Nature 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (see Timmerman and Levy, Ann. Rev. Med. 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate in situ, with marked cytoplasmic processes (dendrites) visible in vitro) and based on the lack of differentiation markers of B cells (CD19 and CD20), T cells (CD3), monocytes (CD14) and natural killer cells (CD56), as determined using standard assays. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells in vivo or ex vivo, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (see Zitvogel et al., Nature Med. 4:594-600, 1998).

09/781,023

Set	Items	Description
S1	67	NEUROBLASTOMA AND APC
S2	37	RD (unique items)
S3	1	S2 AND URINE
S4	1	S2 AND ANTIGEN(W)PRESENTING(W)CELL?

Your SELECT statement is:
s urine and tumor(w)antigen?

Items	File
60	5: Biosis Previews(R)_1969-2002/Oct W3
30	34: SciSearch(R) Cited Ref Sci_1990-2002/Oct W4
1	35: Dissertation Abs Online_1861-2002/Oct
14	71: ELSEVIER BIOBASE_1994-2002/Oct W3
156	73: EMBASE_1974-2002/Oct W3
109	94: JICST-EPlus_1985-2002/Aug W3
1	98: General Sci Abs/Full-Text_1984-2002/Sep
1	135: NewsRx Weekly Reports_1995-2002/Oct W3
22	144: Pascal_1973-2002/Oct W3
21	149: TGG Health&Wellness DB(SM)_1976-2002/Oct W2
37	155: MEDLINE(R)_1966-2002/Oct W3
2	156: ToxFile_1965-2002/Oct W3
47	159: Cancerlit_1975-2002/Sep
2	172: EMBASE Alert_2002/Oct W3
7	266: FEDRIP_2002/Aug
18	399: CA SEARCH(R)_1967-2002/UD=13717
5	434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
12	442: AMA Journals_1982-2002/Oct B2
7	444: New England Journal of Med._1985-2002/Oct W4

19 files have one or more items; file list includes 27 files.

?b 73 and 94
>>>"AND" is invalid in a filelist.

DIALINDEX(R)
(c) 2002 The Dialog Corporation plc

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
?b 73, 94
25oct02 09:35:48 User264783 Session D209.2
$2.44 1.394 DialUnits File411
$2.44 Estimated cost File411
$0.43 TELNET
$2.87 Estimated cost this search
$2.88 Estimated total session cost 1.544 DialUnits

SYSTEM:OS - DIALOG OneSearch
File 73:EMBASE 1974-2002/Oct W3
(c) 2002 Elsevier Science B.V.
***File 73: Alert feature enhanced for multiple files, duplicates** removal, customized scheduling. See HELP ALERT.
File 94:JICST-EPlus 1985-2002/Aug W3
(c)2002 Japan Science and Tech Corp(JST)

Set	Items	Description
S1	265	URINE AND TUMOR(W)ANTIGEN?
S2	0	S1 AND DENDRITIC(W)CELL?
S3	0	S1 AND ANTIGEN(W)PRESENTING(W)CELL?Set Items Description
S1	265	URINE AND TUMOR(W)ANTIGEN?
S2	0	S1 AND DENDRITIC(W)CELL?
S3	0	S1 AND ANTIGEN(W)PRESENTING(W)CELL?
S4	225	S1 NOT PY=>2000
S5	3	S4 AND IMMUNOTHERAPY

5/9/1 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

07666900 EMBASE No: 1999150413
Lack of evidence for an immunosuppressive role for MUC1
Paul S.; Bizouarne N.; Paul A.; Price M.R.; Hansson G.C.; Kieny M.P.; Acres R.B.

S. Paul, Department of Immunology, Transgene S. A, Strasbourg 67082 France
Cancer Immunology Immunotherapy (CANCER IMMUNOL. IMMUNOTHER.) (Germany) 1999, 48/1 (22-28)
CODEN: CIIMD ISSN: 0340-7004
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 46

The in vitro anti-proliferative properties of various supernatants from MUC1-expressing cell lines and of purified preparations of MUC1 were evaluated. We have observed that supernatants from the MUC1- and MUC3-positive cell line T47D, but not from the MUC1- and MUC4-positive cell line MCF7, were able to inhibit proliferation of cells from various haematopoietic cell lines. Although the activity of T47D supernatants could be abrogated by immunodepletion of MUC1, immunopurified MUC1 from T47D was unable to inhibit cell proliferation. Significantly, supernatants from mouse 3T3 cells transfected with a secreted form of MUC1 or from BHK-21 cells infected with a recombinant vaccinia virus coding for the secreted form of MUC1, as well as preparations of purified MUC1 from bile or **urine** , were likewise unable to inhibit T cell proliferation. Surprisingly, a crude mixture of bile mucins had a suppressive effect on T cell growth. Our results suggest that other molecules, such as amino sugars or other mucins, which can associate with MUC1, are likely to be responsible for the observed anti-proliferative effects of T47D cells.

5/9/2 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

06874635 EMBASE No: 1997158963
Urotherapy for patients with cancer
Eldor J.
J. Eldor, Theoretical Medicine Institute, P.O. Box 12142, Jerusalem 97120 Israel
Medical Hypotheses (MED. HYPOTHESES) (United Kingdom) 1997, 48/4 (309-315)
CODEN: MEHYD ISSN: 0306-9877
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 96

Cancer cells release various antigens, some of which appear in the **urine** . Oral autourotherapy is suggested as a new treatment modality for cancer patients. It will provide the intestinal lymphatic system with the many **tumor antigens** against which antibodies may be produced. These antibodies may be pierced through the blood stream and attack the tumor and its cells.

☐ 1: Nat Med 1998 May;4(5):594-600

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.

Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S.

CNRS URA 1301, Institut Gustave Roussy, Villejuif, France.

Dendritic cells (DCs) are professional antigen presenting cells with the unique capacity to induce primary and secondary immune responses in vivo. Here, we show that DCs secrete antigen presenting vesicles, called exosomes, which express functional Major Histocompatibility Complex class I and class II, and T-cell costimulatory molecules. Tumor peptide-pulsed DC-derived exosomes prime specific cytotoxic T lymphocytes in vivo and eradicate or suppress growth of established murine tumors in a T cell-dependent manner. Exosome-based cell-free vaccines represent an alternative to DC adoptive therapy for suppressing tumor growth.

PMID: 9585234 [PubMed - indexed for MEDLINE]